Eslicarbazepine acetate 800 MG Oral Tablet — RxCUI 1482525
RxNorm drug concept · Semantic clinical drug
RxCUI 1482525
Semantic clinical drug · SCD
● Current RxNorm concept 37 FDA products
70 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1482525
Official nameEslicarbazepine acetate 800 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped37
Package NDCs mapped70
Reported Medicaid activity (SDUD)50,618 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Eslicarbazepine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Sure. Eslicarbazepine acetate (brand name Aptiom) is specifically approved to treat partial-onset seizures — that's when a seizure starts in just one area of the brain rather than...
- What exactly is this medicine for? My doctor said it's for seizures — can you tell me more?
- Good news — food doesn't affect how this medicine works, so you can take it with or without a meal, whichever is easier for you. It's taken just once a day, which most people find...
- Can I take this pill with food, or does it have to be on an empty stomach?
🕸️ Concept Web — How Eslicarbazepine acetate 800 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Eslicarbazepine acetate 800 MG Oral Tablet
RxCUI 1482525 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Eslicarbazepine
1482502IN -
Eslicarbazepine acetate
1482501PIN
-
Eslicarbazepine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Aptiom
1482508BN
-
Aptiom
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Eslicarbazepine Oral Tablet
1482506SCDF -
Eslicarbazepine acetate Oral Tablet
2647024SCDFP -
Eslicarbazepine Oral Product
1482504SCDG -
Eslicarbazepine Pill
1482505SCDG -
Eslicarbazepine acetate Oral Product
2662353SCDGP -
Eslicarbazepine acetate Pill
2660612SCDGP -
Eslicarbazepine Oral Tablet [Aptiom]
1482510SBDF -
Eslicarbazepine acetate Oral Tablet [Aptiom]
2654181SBDFP - +5 more in this family
-
Eslicarbazepine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Eslicarbazepine acetate 800 MG
1482524SCDC -
Eslicarbazepine acetate 800 MG Oral Tablet [Aptiom]
1482527SBD -
Eslicarbazepine acetate 800 MG [Aptiom]
1482526SBDC
-
Eslicarbazepine acetate 800 MG
-
Packs 2
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 16 of 21 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
{7 (eslicarbazepine acetate 400 MG Oral Tablet) / 7 (eslicarbazepine acetate 800 MG Oral Tablet) } Pack
GPCK · 1491642 -
Eslicarbazepine acetate 800 MG
SCDC · 1482524 -
Eslicarbazepine Oral Tablet
SCDF · 1482506 -
Eslicarbazepine acetate Oral Tablet
SCDFP · 2647024 -
Eslicarbazepine Oral Product
SCDG · 1482504 -
Eslicarbazepine Pill
SCDG · 1482505 -
Eslicarbazepine acetate Oral Product
SCDGP · 2662353 -
Eslicarbazepine acetate Pill
SCDGP · 2660612
Brand-Name Concepts
-
Eslicarbazepine acetate 800 MG Oral Tablet [Aptiom]
SBD · 1482527 -
{7 (eslicarbazepine acetate 400 MG Oral Tablet [Aptiom]) / 7 (eslicarbazepine acetate 800 MG Oral Tablet [Aptiom]) } Pack [Aptiom Titration Sample Pack]
BPCK · 1491643 -
Eslicarbazepine acetate 800 MG [Aptiom]
SBDC · 1482526 -
Eslicarbazepine Oral Tablet [Aptiom]
SBDF · 1482510 -
Eslicarbazepine acetate Oral Tablet [Aptiom]
SBDFP · 2654181 -
Aptiom Oral Product
SBDG · 1482511 -
Aptiom Pill
SBDG · 1482512 -
Aptiom
BN · 1482508
📦 FDA Products & Package NDCs
37 products · 70 package NDCs
70 package NDCs map to RxCUI 1482525 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 13668-0538-05 | 500 TABLET in 1 BOTTLE (13668-538-05) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0538-30 | 30 TABLET in 1 BOTTLE (13668-538-30) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0538-60 | 60 TABLET in 1 BOTTLE (13668-538-60) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0539-05 | 500 TABLET in 1 BOTTLE (13668-539-05) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0539-30 | 30 TABLET in 1 BOTTLE (13668-539-30) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0539-60 | 60 TABLET in 1 BOTTLE (13668-539-60) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0540-05 | 500 TABLET in 1 BOTTLE (13668-540-05) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0540-30 | 30 TABLET in 1 BOTTLE (13668-540-30) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0540-60 | 60 TABLET in 1 BOTTLE (13668-540-60) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0541-05 | 500 TABLET in 1 BOTTLE (13668-541-05) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0541-30 | 30 TABLET in 1 BOTTLE (13668-541-30) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 13668-0541-60 | 60 TABLET in 1 BOTTLE (13668-541-60) | Eslicarbazepine acetate | Torrent Pharmaceuticals Limited | 2025-05-06 |
| 31722-0428-30 | 30 TABLET in 1 BOTTLE (31722-428-30) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0428-32 | 10 BLISTER PACK in 1 CARTON (31722-428-32) / 10 TABLET in 1... | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0429-30 | 30 TABLET in 1 BOTTLE (31722-429-30) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0429-32 | 10 BLISTER PACK in 1 CARTON (31722-429-32) / 8 TABLET in 1... | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0430-32 | 10 BLISTER PACK in 1 CARTON (31722-430-32) / 10 TABLET in 1... | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0430-60 | 60 TABLET in 1 BOTTLE (31722-430-60) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0430-90 | 90 TABLET in 1 BOTTLE (31722-430-90) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0431-30 | 30 TABLET in 1 BOTTLE (31722-431-30) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0431-32 | 10 BLISTER PACK in 1 CARTON (31722-431-32) / 10 TABLET in 1... | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 31722-0431-90 | 90 TABLET in 1 BOTTLE (31722-431-90) | Eslicarbazepine acetate | Camber Pharmaceuticals, Inc. | 2023-08-03 |
| 43598-0684-30 | 30 TABLET in 1 BOTTLE (43598-684-30) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 43598-0685-30 | 30 TABLET in 1 BOTTLE (43598-685-30) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 43598-0686-60 | 60 TABLET in 1 BOTTLE (43598-686-60) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 43598-0686-90 | 90 TABLET in 1 BOTTLE (43598-686-90) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 43598-0687-30 | 30 TABLET in 1 BOTTLE (43598-687-30) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 43598-0687-90 | 90 TABLET in 1 BOTTLE (43598-687-90) | Eslicarbazepine Acetate | Dr.Reddys Laboratories Inc | 2025-05-06 |
| 51407-0779-30 | 30 TABLET in 1 BOTTLE (51407-779-30) | Eslicarbazepine Acetate | Golden State Medical Supply, Inc. | 2025-05-12 |
| 51407-0780-30 | 30 TABLET in 1 BOTTLE (51407-780-30) | Eslicarbazepine Acetate | Golden State Medical Supply, Inc. | 2025-05-12 |
| 51407-0781-60 | 60 TABLET in 1 BOTTLE (51407-781-60) | Eslicarbazepine Acetate | Golden State Medical Supply, Inc. | 2025-05-12 |
| 51407-0782-30 | 30 TABLET in 1 BOTTLE (51407-782-30) | Eslicarbazepine Acetate | Golden State Medical Supply, Inc. | 2025-05-12 |
| 59746-0717-10 | 1000 TABLET in 1 BOTTLE (59746-717-10) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0717-30 | 30 TABLET in 1 BOTTLE (59746-717-30) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0717-90 | 90 TABLET in 1 BOTTLE (59746-717-90) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0718-10 | 1000 TABLET in 1 BOTTLE (59746-718-10) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0718-30 | 30 TABLET in 1 BOTTLE (59746-718-30) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0718-90 | 90 TABLET in 1 BOTTLE (59746-718-90) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0719-05 | 500 TABLET in 1 BOTTLE (59746-719-05) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0719-30 | 30 TABLET in 1 BOTTLE (59746-719-30) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0719-60 | 60 TABLET in 1 BOTTLE (59746-719-60) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0719-90 | 90 TABLET in 1 BOTTLE (59746-719-90) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0720-05 | 500 TABLET in 1 BOTTLE (59746-720-05) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0720-30 | 30 TABLET in 1 BOTTLE (59746-720-30) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 59746-0720-90 | 90 TABLET in 1 BOTTLE (59746-720-90) | Eslicarbazepine Acetate | Jubilant Cadista Pharmaceuticals Inc. | 2026-05-01 |
| 60505-4658-03 | 30 TABLET in 1 BOTTLE (60505-4658-3) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4658-09 | 90 TABLET in 1 BOTTLE (60505-4658-9) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4659-03 | 30 TABLET in 1 BOTTLE (60505-4659-3) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4659-09 | 90 TABLET in 1 BOTTLE (60505-4659-9) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4660-06 | 60 TABLET in 1 BOTTLE (60505-4660-6) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
Observed labelers:
Jubilant Cadista Pharmaceuticals Inc. (13) ·
Torrent Pharmaceuticals Limited (12) ·
Camber Pharmaceuticals, Inc. (10) ·
Sumitomo Pharma America, Inc. (9) ·
Apotex Corp. (8) ·
Dr.Reddys Laboratories Inc (6)
· +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.